Assess whether a CMO finding is a delay or a refuse-to-file risk (95a971)

Situation

In a safety team sitting on a new disproportionate signal, disproportionate reporting signal workbook is the evidence after a literature paper the 505(b)(2) package leans on getting retracted. 505(b)(2) development lead has to pick A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences Pharmacovigilance close using disproportionate reporting signal workbook.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose A CMO finding is a delay / A refuse-to-file risk using disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• A literature paper the 505(b)(2) package leans on getting retracted is noise around an already-controlled Pharmacovigilance process in a safety team sitting on a new disproportionate signal, given disproportionate reporting signal workbook.
• A literature paper the 505(b)(2) package leans on getting retracted is the event in disproportionate reporting signal workbook that forces A CMO finding is a delay for 505(b)(2) development lead under Pharma & Life Sciences.
• Disproportionate reporting signal workbook shows a one-file miss after a literature paper the 505(b)(2) package leans on getting retracted, not a Pharmacovigilance program failure.
• Disproportionate reporting signal workbook cannot decide a CMO finding is yet after a literature paper the 505(b)(2) package leans on getting retracted; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

Analysis required

• Check whether disproportionate reporting signal workbook supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move a CMO finding is for 505(b)(2) development lead.

Recommendation